Table 1.
Univariable analysis and multivariable analysis of the model and clinical features.
| Author | Year | List 1 | List 2 | List 3 | List 4 | List 5 | List 6 | List 7 | List 8 | MINORS Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Nakamura, S. | 2002 | 1 | 0 | 2 | 2 | 1 | 2 | 2 | 0 | 10(excluded) |
| Kim, H. J (10) | 2007 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
| Loo, C. E (11) | 2011 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Kim, T. H (12) | 2012 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Hu, J.X (13) | 2012 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12 |
| Mukhtar, R. A (14) | 2013 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 0 | 12 |
| Tomida, K (15) | 2014 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
| Hu, Y (16) | 2014 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12 |
| Xiao, R (17) | 2014 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
| Zhou, Q (18) | 2014 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 0 | 12 |
| Bansal, G. J (19) | 2016 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Liao, C. W (20) | 2016 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12 |
| Ballesio, L (21) | 2017 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Eom, H. J (22) | 2017 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 12 |
| Li, M (23) | 2017 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Fukada, I (24) | 2018 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Goorts, B (25) | 2018 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Shin, S. U (26) | 2018 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Zhang, D (27) | 2018 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Shao, Z. Z (28) | 2018 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
| Xu, C.J (29) | 2018 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 |
| Ling, D. C (30) | 2019 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12 |
| Liu, D.Z (31) | 2019 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 14 |
| Zhang, Q.C (32) | 2019 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12 |
MINORS: Methodological index for non-randomized studies; List 1: A clearly stated aim; List 2: Inclusion of consecutive patients; List 3: Prospective collection of data; List 4: Endpoints appropriate to the aim of the study; List 5: Unbiased assessment of the study endpoint; List 6: Follow-up period appropriate to the aim of the study; List 7: Loss to follow up less than 5%; List 8: Prospective calculation of the study size.